Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

MedX Health completes private placement of convertible notes for C$2.8m

MedX Health has completed a private placement of Series IV convertible notes totaling C$2.8 million. The notes mature on Dec. 31, 2028, bear interest at 6% p.a. (paid quarterly) and are convertible into units at maturity at C$0.10 each; each unit consists of one common share and one-half warrant, and one whole warrant has an exercise price of C$0.125. Insiders participated in the placement; C$2.4 million was used to replace the Series I notes and the remainder will be used to further develop the telemedicine platform “SIAscopy on DermSecure,” expand into occupational medicine, and for general corporate purposes. The company was not profitable over the past 12 months, trades at $0.01 with a market capitalization of $30.7 million, and has a current ratio of 1.29. » Altro su de.investing.com
MedX Health raises $2.7m through first tranche of convertible note

MedX Health has completed the first tranche of a private placement of convertible notes totaling $2.7m; the placement may reach up to $5m in total. The series IV notes have a par value of $50,000 each, pay 6% annual interest, mature on 31 December 2028 and are convertible into units at $0.10 per unit; warrants are exercisable at $0.125. Proceeds are to be used to repay the series I, to further develop the SIAscopy technology on DermSecure, to expand into occupational medicine and for general corporate purposes; the company remains unprofitable and reported a 63% decline in revenue over the past 12 months. » Altro su de.investing.com
MedX Health raises C$1.96m in non‑brokered private placement

MedX Health closed the final tranches of a non‑brokered private placement for accredited investors, raising a total of C$1.96m. The placement issued 26,139,999 units at C$0.075 each; each unit consists of one common share and one half warrant, with each whole warrant exercisable within one year at C$0.10. Two insiders subscribed for units; finders received small cash commissions and warrants, and the issued securities are subject to a hold period of four months plus one day. The proceeds will fund further development of the telemedicine platform SIAscopy on DermSecure, the market launch in occupational medicine and general corporate purposes; the stock is up more than 21% year‑to‑date despite profitability issues. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, MedX Health Co. Aktie ha registrato ricavi pari a 73,03K € e un utile netto di -988,44K €

(EUR)	giugno 2026	YoY
Ricavi	73,03K	32,33%
Utile lordo	20,45K	86,05%
Utile netto	-988,44K	20,47%
EBITDA	-740,91K	29,10%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	7,06 Mln €
Numero di azioni	327,93 Mln
Massimo/minimo a 52 settimane	0,0431 € - 0,000689 €
Dividendi	No
Beta	1,80
Rapporto P/E	-1,80
Rapporto PEG	0,13
Rapporto P/B	-1,06
Rapporto P/S	19,90

Profilo aziendale

MedX Health Corp, ein Medizintechnik- und Softwareunternehmen, entwickelt, produziert und vertreibt in Kanada, den Vereinigten Staaten und international Hautscreeninggeräte und Phototherapiegeräte zur Schmerzlinderung und Gewebereparatur. Das Unternehmen bietet SIAscopy an, eine medizinische Gerätetechnologie, mit der die Haut auf verdächtige Muttermale und Läsionen gescannt werden kann; phototherapeutische medizinische Geräte, die Lichtenergie in Form von Low-Level-Lasern und LEDs zur Behandlung von Schmerzen und Gewebeschäden auf dem Rehabilitationsmarkt einsetzen; und SIAMETRICS, SIMSYS und MoleMate, die Echtzeitbilder für Ärzte und Dermatologen erstellen, um verschiedene Arten von Muttermalen oder Läsionen innerhalb von Sekunden zu bewerten. Es betreibt die Telemedizinplattform DermSecure, die den webbasierten Betrieb seiner SIAscopy-Scantechnologie ermöglicht und dem Unternehmen erlaubt, seine Technologie in Netzwerken von Drittanbietern einzusetzen, von denen aus die Bilder von Muttermalen und Läsionen von Patienten zusammen mit anderen relevanten Patienteninformationen an Fachärzte zur Fernbeurteilung weitergeleitet werden können. Das Unternehmen wurde 1999 gegründet und hat seinen Hauptsitz in Mississauga, Kanada.